- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04204096
Immune Equivalence Between Multi-dose and Single Dose Formulation of Vi-DT and Their Overall Safety (Phase III)
A Phase III, Multicenter, Observer Blind, Randomized, Controlled Study to Evaluate Immune Equivalence of Multi-dose Formulation Against Single-dose Formulation of Vi-DT Typhoid Conjugate Vaccine and Safety in Healthy Filipino......
This is a multicenter, randomized, observer-blinded, controlled, immune equivalence study of a multi-dose (MD) formulation with 2PE preservative of SK bioscience Vi-DT compared to single dose (SD) formulation without preservative of SK bioscience Vi-DT in participant (6 months - 45 years) including safety population.
The study objectives are as follows:
- Primary objective. Demonstrate the immune equivalence as measured by anti-Vi IgG Geometric Mean Titer (GMT) of multi dose formulation against single dose formulation of Vi-DT (18-45 year age stratum), at 4 weeks after a single dose.
- Secondary objective 1. Demonstrate the immune equivalence as measured by seroconversion rates of anti-Vi IgG antibody titres of multi dose formulation against single dose formulation of Vi-DT vaccine (18-45 year age stratum) at 4 weeks after a single dose.
- Secondary objective 2. Describe safety profile in all age strata combined (age 6 months - 45 years old) and in each age stratum, at 4 weeks after a single dose of SD/MD formulation/control (Meningococcal Conjugate Vaccine).
There are total 5 scheduled visits as follows:
- Visit 1(D-7 to 0): Screening
- Visit 2(D0): Enrollment, vaccination, safety follow-up and blood collection for immunogenicity assessment (only for subjects 18 years old and above)
- Visit 3(D7): Safety follow-up
- Visit 4(D28): Safety follow-up and blood collection for immunogenicity assessment (only for subjects 18 years old and above)
- V5(D168): Safety follow-up
Study Overview
Status
Conditions
Detailed Description
The vaccines will be administered to 1,500 healthy participants of 6 months to 45 years of age and followed up for 24 weeks after the injection for safety. Adult participants (N=500) will be followed up for immunogenicity at 4 weeks and all participants till 24 weeks for safety post single dose of either MD & SD formulations. 300 healthy participants will be given control vaccine (locally available licensed Meningococcal conjugate vaccine) to check the background safety events. The primary objective is to demonstrate the equivalence of immunogenicity as measured by anti-Vi IgG GMT titer at 4 weeks after a single dose of MD/SD formulation in adults. The secondary objective is to demonstrate the equivalence of immunogenicity in terms of seroconversion rates as measured by anti-Vi IgG ELISA antibody titers, at 4 weeks after a single dose of MD/SD formulation in adults. A descriptive evaluation of safety at 4 and 24 weeks post single dose of (SD/MD/Meningococcal vaccine), will be performed. The Vi-DT vaccine from both MD & SD formulations will be administered as a single dose of 25 µg/0.5 mL.
Eligible participants enrolled into the study will be randomized into one of the three study groups within each age stratum of 6 months to less than 2 years, 2 to less than 18 years, and 18 to 45 years. Participants will be observed at the study site for 30 minutes after vaccination for safety assessment. Solicited adverse events will be recorded on a diary card during 7 days after vaccination. Unsolicited adverse events will be recorded during the 4 weeks after vaccination. Serious adverse events will be recorded during the entire study period. With the exception of designated study site personnel responsible for vaccine administration, site investigators, study nurse, and those assessing clinical outcomes, and data analysts will be blinded to vaccine allocation until data base lock for the final analysis.
Blood samples will be collected at baseline prior to vaccination and at 4 weeks post vaccination from adults (18-45 years) for immunogenicity assessment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Manila, Philippines, 1000
- University of the Philippines Manila-National Institutes of Health
-
-
Laguna
-
Calamba, Laguna, Philippines, 4027
- Lingga Health Research Center
-
San Pablo City, Laguna, Philippines, 4000
- Magcase Health Center
-
-
Metro Manila
-
Muntinlupa, Metro Manila, Philippines, 1772
- Putatan Research Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Healthy participants 6 months to 45 years of age at enrollment
- Participants/Parent(s)/LAR who have voluntarily given informed consent/assent
- Participants/Parent(s)/LAR willing to follow the study procedures of the study and available for the entire duration of the study
Exclusion Criteria:
- Child with a congenital abnormality
- Participant who has already received meningococcal conjugate vaccine
- Participants concomitantly enrolled or scheduled to be enrolled in another trial
- Known history of immune function disorders including immunodeficiency diseases (Known HIV infection or other immune function disorders)
- Chronic use of systemic steroids (>2 mg/kg/day or >20 mg/day prednisone equivalent for periods exceeding 10 days), cytotoxic or other immunosuppressive drugs
- Receipt of blood or blood-derived products in the past 3 months
- Participant with a previously ascertained or suspected disease caused by S. Typhi (confirmed either clinically, serologically or microbiologically)
- Participant who has had household contact with and/or intimate exposure to an individual with laboratory-confirmed S. Typhi
- Individual who has previously received a typhoid vaccine
- Participant who has received other vaccines from 1 month prior to test vaccination or planned to receive any vaccine within 1 month (except a measles containing vaccine as per government vaccination campaign)
- Known history or allergy to vaccines or other medications
- History of uncontrolled coagulopathy or blood disorders
- Any abnormality or chronic disease which in the opinion of the investigator might be detrimental for the safety of the participant and interfere with the assessment of the study objectives
- Any female participant who is lactating, pregnant* or planning for pregnancy during the course of study period
- Participants/Parent(s)/LAR planning to move from the study area before the end of study period
- As per Investigator's medical judgement individual could be excluded from the study in spite of meeting all inclusion/exclusion criteria mentioned above
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vi-DT Multi-dose
|
Other Names:
|
Experimental: Vi-DT Single-dose
|
Other Names:
|
Active Comparator: Control
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Geometric Mean Titers (GMT) of anti-Vi IgG
Time Frame: At 4 weeks (28 days) post vaccination of Vi-DT (MD/SD)
|
If the 95% confidence interval of the ratio of GMT estimate of Vi-DT(MD) over GMT of Vi-DT(SD) is located within the bounds of 0.67to 1.5, then Vi-DT (MD) is equivalent to Vi-DT (SD) in terms of GMT of anti-Vi IgG with significance level of 0.05.
|
At 4 weeks (28 days) post vaccination of Vi-DT (MD/SD)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Seroconversion rates of anti-Vi IgG ELISA antibody titres
Time Frame: At 4 weeks (28 days) from baseline (Day 0; before vaccination of Vi-DT (MD/SD)
|
If the 95% confidence interval of the estimate of difference of seroconversion rate between Vi-DT (MD) and Vi-DT (SD) at 4 weeks (Day 28) is located within the bounds -10% to 10%, then Vi-DT (MD) is equivalent to Vi-DT (SD) in terms of sero-conversion rate, which is defined as 4 fold increase of anti Vi IgG from baseline with significance level of 0.05.
|
At 4 weeks (28 days) from baseline (Day 0; before vaccination of Vi-DT (MD/SD)
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Safety endpoints by each formulation and overall and within each age stratum
Time Frame: Solicited AEs during the 7 days after vaccination/Unsolicited AEs during 4 weeks (28 days) after vaccination/SAEs during the entire study period
|
|
Solicited AEs during the 7 days after vaccination/Unsolicited AEs during 4 weeks (28 days) after vaccination/SAEs during the entire study period
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Josefina C Carlos, MD, University of the East-Ramon Magsaysay Memorial Medical Center Inc.
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- IVI T004
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Typhoid
-
University of Maryland, BaltimoreActive, not recruitingTyphoid VaccinationUnited States
-
National Institute of Allergy and Infectious Diseases...Completed
-
University of OxfordCompletedTyphoid Vaccine on Sleep
-
University of Maryland, BaltimoreRecruitingTyphoid and/or Cholera VaccinationUnited States
-
International Centre for Diarrhoeal Disease Research...Recruiting
-
International Vaccine InstituteUniversity of Cambridge; Institute of Tropical Medicine, Belgium; Institut National...RecruitingTyphoid FeverCongo, The Democratic Republic of the
-
International Vaccine InstituteBill and Melinda Gates Foundation; SK Bioscience Co., Ltd.Completed
-
Helsinki University Central HospitalUnknown
-
Christian Medical College, Vellore, IndiaImperial College London; University College, London; Bill and Melinda Gates FoundationRecruiting
-
Foundation for Innovative New Diagnostics, SwitzerlandAga Khan UniversityCompleted
Clinical Trials on Vi-DT (Multi-dose formulation)
-
International Vaccine InstituteSK Chemicals Co., Ltd.Completed
-
PT Bio FarmaIndonesia UniversityActive, not recruiting
-
International Vaccine InstituteBill and Melinda Gates Foundation; SK Bioscience Co., Ltd.Completed
-
International Vaccine InstituteSK Bioscience Co., Ltd.Unknown
-
International Centre for Diarrhoeal Disease Research...Recruiting
-
PT Bio FarmaCompletedSafety Issues | ImmunogenicityIndonesia
-
Domain Therapeutics SARecruitingSolid Tumor, AdultFrance, Belgium
-
PT Bio FarmaCompletedSafety Issues | ImmunogenicityIndonesia
-
PT Bio FarmaCompleted
-
GlaxoSmithKlineActive, not recruitingHepatitis B, ChronicTaiwan, Belgium, Thailand, Germany, Spain, Hong Kong, United Kingdom, France, Poland